[go: up one dir, main page]

DK2258351T3 - Granula indeholdende lansoprazol i stor mængde - Google Patents

Granula indeholdende lansoprazol i stor mængde

Info

Publication number
DK2258351T3
DK2258351T3 DK10178017.9T DK10178017T DK2258351T3 DK 2258351 T3 DK2258351 T3 DK 2258351T3 DK 10178017 T DK10178017 T DK 10178017T DK 2258351 T3 DK2258351 T3 DK 2258351T3
Authority
DK
Denmark
Prior art keywords
large quantity
granules containing
containing lansoprazole
lansoprazole
granules
Prior art date
Application number
DK10178017.9T
Other languages
English (en)
Inventor
Toshihiro Shimizu
Yoshinori Nakano
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19136997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2258351(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK2258351T3 publication Critical patent/DK2258351T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK10178017.9T 2001-10-17 2002-10-16 Granula indeholdende lansoprazol i stor mængde DK2258351T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001319444 2001-10-17
EP02775358A EP1459737B1 (en) 2001-10-17 2002-10-16 Granules containing acid-unstable chemical in large amount

Publications (1)

Publication Number Publication Date
DK2258351T3 true DK2258351T3 (da) 2013-08-26

Family

ID=19136997

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02775358.1T DK1459737T3 (da) 2001-10-17 2002-10-16 Granulat indeholdende syreustabilt kemisk middel i stor mængde
DK10178017.9T DK2258351T3 (da) 2001-10-17 2002-10-16 Granula indeholdende lansoprazol i stor mængde

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02775358.1T DK1459737T3 (da) 2001-10-17 2002-10-16 Granulat indeholdende syreustabilt kemisk middel i stor mængde

Country Status (9)

Country Link
US (1) US8105626B2 (da)
EP (2) EP2258351B1 (da)
CN (1) CN100562317C (da)
CA (1) CA2463690C (da)
CY (2) CY1113763T1 (da)
DK (2) DK1459737T3 (da)
ES (2) ES2426723T3 (da)
PT (2) PT1459737E (da)
WO (1) WO2003032953A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003273000A1 (en) * 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
CA2518780C (en) * 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
AU2004271747A1 (en) * 2003-09-18 2005-03-24 Altana Pharma Ag Use of known active ingredients as radical scavengers
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005084649A1 (ja) * 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited 安定なカプセル剤
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US8871273B2 (en) 2005-02-25 2014-10-28 Takeda Pharmaceutical Company Limited Method for producing granules
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
AU2006242067B2 (en) * 2005-04-28 2012-03-29 Eisai R & D Management Co., Ltd. Stabilized composition
US9040564B2 (en) * 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
EP2018160B1 (en) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
WO2008081891A1 (ja) * 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
BRPI0818286A2 (pt) * 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
AU2009215514B9 (en) 2008-02-20 2014-01-30 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
EP2535045A1 (en) * 2011-06-15 2012-12-19 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical composition of lansoprazole
WO2013141827A1 (en) * 2012-03-21 2013-09-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Enteric coated solid pharmaceutical compositions for proton pump inhibitors
US20150209432A1 (en) 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
CN104414994A (zh) * 2013-08-24 2015-03-18 湖北欧立制药有限公司 兰索拉唑肠溶胶囊及其制备工艺
CN104546790A (zh) * 2013-10-15 2015-04-29 悦康药业集团有限公司 一种兰索拉唑肠溶胶囊及其制备方法
CN104173342A (zh) * 2014-07-30 2014-12-03 福州闽海药业有限公司 一种右旋兰索拉唑组合物
CN105769824A (zh) * 2014-12-16 2016-07-20 四川海思科制药有限公司 一种兰索拉唑缓释胶囊及其制备方法
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) * 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN111789808A (zh) * 2019-04-08 2020-10-20 生达化学制药股份有限公司 口服医药组成物及其结构

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0832625B2 (ja) 1987-01-29 1996-03-29 武田薬品工業株式会社 有核顆粒およびその製造法
JPH05255088A (ja) 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JPH05139964A (ja) 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
ES2145102T3 (es) 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd Formulacion que comprende una sustancia antibacteriana y una sustancia antiulcerosa.
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
JP2676319B2 (ja) 1994-02-09 1997-11-12 大洋薬品工業株式会社 塩酸ニカルジピンの徐放剤用製剤およびこれを利用した徐放化製剤
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
JP2762998B2 (ja) 1997-04-25 1998-06-11 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1671799A (en) 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
JP2002501897A (ja) * 1998-01-30 2002-01-22 セプラコール， インク． Ｒ−ランソプラゾール組成物及び方法
JP4127740B2 (ja) 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
WO1999053918A1 (en) 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ATE481090T1 (de) 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
TW404832B (en) 1999-01-27 2000-09-11 Nang Kuang Pharmaceutical Co L The oral medicine with good stability cotaining the omeprazole or the analogues
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1108425B1 (en) * 1999-12-16 2005-06-08 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles
KR100775802B1 (ko) 2000-04-28 2007-11-12 다케다 야쿠힌 고교 가부시키가이샤 광학 활성 술폭시드 유도체의 제조 방법
AU2003250468A1 (en) * 2002-08-16 2004-03-03 Themis Laboratories Private Limited A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles

Also Published As

Publication number Publication date
CN1571659A (zh) 2005-01-26
CA2463690C (en) 2011-08-23
CY1114668T1 (el) 2016-10-05
EP1459737A4 (en) 2007-09-26
EP1459737A1 (en) 2004-09-22
WO2003032953A1 (en) 2003-04-24
EP1459737B1 (en) 2012-09-26
EP2258351A2 (en) 2010-12-08
CA2463690A1 (en) 2003-04-24
PT1459737E (pt) 2012-11-26
CN100562317C (zh) 2009-11-25
ES2426723T3 (es) 2013-10-24
CY1113763T1 (el) 2016-07-27
EP2258351B1 (en) 2013-06-19
EP2258351A3 (en) 2011-10-12
PT2258351E (pt) 2013-07-29
US20050003005A1 (en) 2005-01-06
DK1459737T3 (da) 2013-01-02
ES2392960T3 (es) 2012-12-17
US8105626B2 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
DK2258351T3 (da) Granula indeholdende lansoprazol i stor mængde
DE50114911D1 (de) Feststoffgranulate mit monodisperser korngrössenverteilung
DE60238422D1 (de) Optimierte dosierung bei paclitaxelhaltigen stents
PT1043239E (pt) Recipiente com lados colapsaveis
FR2801195B3 (fr) Article absorbant
DE50111881D1 (de) MRAM-Speicher
AR028098A1 (es) Bebida estable en el ambiente
DE60127533D1 (de) Prebiotische substanzen enthaltende ernährungszusammensetzungen
DK1218009T3 (da) Quetiapingranulater
DK1208015T3 (da) Lagerindretning
ITMI20011128A0 (it) Dispositivo dosatore
DE60113022D1 (de) NOx-Speicherkapazität
DE60116985D1 (de) Dosiervorrichtung mit optimierter Einstellung
DE60122771D1 (de) Feines zeolithteilchen
ATE283629T1 (de) Deltamethrinhaltiges, wasserdispergierbares granulat
FI20001260L (fi) Kontti
ITMO990208A0 (it) Impianto per il dosaggio di componenti in polvere o in granuli
DE60027891D1 (de) Granulare waschmittelzusammensetzung enthaltend zeolith map
DE50104260D1 (de) Behälter
ITMI20001681A0 (it) Dispositivo dosatore
ATA15302000A (de) Aufbewahrungseinrichtung
FI20001704A0 (fi) Kontti
FI20012490A0 (fi) Järjestely vesisäiliössä
FI5027U1 (fi) Yläpohjarakenne
DK1324661T3 (da) Deltamethrinholdigt vanddispergerbart granulat